Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGIN2: Gemcitabine and Ivonescimab in Advanced NSCLC
NCT07158489Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Aug 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07158489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158489.